ReviewCanadian Urological Association journal = Journal de l'Association des urologues du Canada2025
Neoadjuvant systemic therapy in managing locally advanced renal cancer before surgery A systematic review and meta-analysis.
Review in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neoadjuvant therapies for clear cell renal cell carcinoma: review of current evidence and future applications.World journal of urology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe aimed to estimate the effectiveness and safety of neoadjuvant systemic therapy in locally advanced renal tumor patients who undergo a nephrectomy in terms of survival, tumor response, and surgical feasibility.
methodsWe included clinical trials, quasi-experimental studies, and cohort studies providing data on the use of neoadjuvant systemic therapy in managing locally advanced renal cancer before surgery in adult patients. The primary outcomes were cancer-specific survival (CSS), overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS). We performed a meta-analysis of proportions in R and assessed the risk of bias with the MINORS tool.
resultsNine studies were included for qualitative synthesis and seven for meta-analysis. All non-randomized studies assessed had a low risk of bias against the stated objective by clearly stating their purpose. Likewise, most studies had a low risk of bias in the consecutive inclusion of patients, contemporary groups, and equivalence. Change in tumor size ranged from -50% to +7.9%. Partial response was achieved in 26% (95% confidence interval 15-42).
conclusionsNeoadjuvant therapy in locally advanced renal tumors ≥T3 or N1 has shown positive results regarding clinical tumor regression in about one-third of the patients. It is feasible and safe in this high-risk population.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.